Uncertainty at Ambrx as biotech loses CEO, takes hard look at pipeline

Two months after revealing that a heart failure collaboration with Bristol Myers Squibb had hit the buffers, Ambrx Biopharma has lost its CEO and announced a “strategic review” of its pipeline.